Table 6.
Univariate and Multivariate Cox Regression Analysis for Predicting Recurrence in Patients with Paroxysmal AF
| Parameters | UV | MV Model 1 | MV Model 2 | |||
|---|---|---|---|---|---|---|
| HR (95% CI) | P value | HR (95% CI) | P value | HR (95% CI) | P value | |
| Age | 1.03 (1.01–1.06) | 0.011 | ||||
| Female sex | 2.48 (1.39–4.40) | 0.002 | 1.09 (1.15–3.79) | 0.015 | ||
| BMI | 0.94 (0.86–1.02) | 0.123 | ||||
| AF duration | 1.00 (0.99–1.01) | 0.664 | ||||
| Hypertension | 1.08 (0.65–1.80) | 0.768 | ||||
| Diabetes mellitus | 1.20 (0.67–2.15) | 0.539 | ||||
| CHD | 1.21 (0.61–2.39) | 0.583 | ||||
| CHF | 1.45 (0.62–3.38) | 0.391 | ||||
| Previous stroke | 3.00 (1.28–7.02) | 0.011 | 3.40 (1.43–8.11) | 0.006 | ||
| PAD | 3.20 (1.36–7.48) | 0.008 | 2.88 (1.17–7.10) | 0.022 | ||
| BNP | 1.00 (0.99–1.00) | 0.323 | ||||
| eGFR | 0.98 (0.97–0.99) | <0.001 | 0.98 (0.97–0.99) | 0.020 | ||
| LAD | 1.11 (1.05–1.16) | <0.001 | 1.08 (1.03–1.14) | 0.002 | ||
| LVEF | 1.01 (0.94–1.08) | 0.810 | ||||
| Antiarrhythmic drugs | 0.51 (0.28–0.92) | 0.026 | 0.64 (0.35–1.15) | 0.136 | 0.67 (0.36–1.26) | 0.220 |
| PLR | 1.00 (1.00–1.01) | 0.010 | 1.00 (0.99–1.01) | 0.156 | 1.00 (0.99–1.01) | 0.363 |
| APPLE score | 2.16 (1.63–2.86) | <0.001 | 1.89 (1.37–2.60) | <0.001 | ||
| CHA2DS2‑VASc score | 1.34 (1.15–1.56) | <0.001 | 1.19 (1.00–1.40) | 0.047 | ||
Abbreviations: AF, atrial fibrillation; BMI, body mass index; CHD, coronary heart disease; CHF, chronic heart failure; PAD, peripheral artery disease; COPD, chronic obstructive pulmonary disease; SBP, systolic blood pressure; HR, heart rate; FBG, fasting blood-glucose; BNP, brain natriuretic peptide; eGFR, Estimated glomerular filtration rate; BUA, blood uric acid; Alb, albumin; LAD, left atrial diameter; LVED, left ventricular end diastolic diameter; LVEF, left ventricular ejection fraction; PLR, platelet to lymphocyte ratio.